Outlook Therapeutics stock prices $5M offering at $0.25 per share amid Nasdaq plunge and biotech funding squeeze

NodeGuardian · 2026-03-31T12:36:10+00:00

Outlook Therapeutics has announced a $5 million public offering of 20 million shares and warrants at $0.25 each, causing a 39% stock drop due to dilution concerns. The offering aims to meet liquidity needs as the company awaits FDA approval for its product.

NodeGuardian

2026-03-31 12:36:10

Abstract generation in progress

Outlook Therapeutics has priced a $5 million public offering of 20 million shares and warrants at $0.25 each, leading to a 39% stock drop due to dilution fears. The offering aims to address acute liquidity needs for the retina disease specialist as its ONS-5010/LYTENAVA product awaits US FDA approval, despite successful European launches. This move highlights the company’s financial strain and the high cost of capital for pre-revenue biotech firms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes